1. Home
  2. SNY
  3. SNY News

Latest Sanofi ADS (SNY) News on May 10, 2025

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
SNY

Benzinga

2 days ago

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

Sanofi exec tells biotechs not to scrimp on clinical trial design
SNY

Clinical Trials Arena

2 days ago

Sanofi exec tells biotechs not to scrimp on clinical trial design

Novavax to Report First-Quarter Earnings: Is a Beat in Store?
SNY

Zacks

5 days ago

Novavax to Report First-Quarter Earnings: Is a Beat in Store?

European Firms Fare Better Than Feared Through Early Trade Pain
SNY

Bloomberg

5 days ago

European Firms Fare Better Than Feared Through Early Trade Pain

Sanofi: Information concerning the total number of voting rights and shares - March 2025
SNY

GlobeNewswire

8 days ago

Sanofi: Information concerning the total number of voting rights and shares - March 2025

Sanofi (ENXTPA:SAN) Announces €4 Per Share Dividend And New Compensation Committee Chair
SNY

Simply Wall St.

8 days ago

Sanofi (ENXTPA:SAN) Announces €4 Per Share Dividend And New Compensation Committee Chair

Sanofi (SNY, Financials) Completes Opella Deal, Creates Consumer Health Leader
SNY

GuruFocus.com

9 days ago

Sanofi (SNY, Financials) Completes Opella Deal, Creates Consumer Health Leader

SNY

MT Newswires

9 days ago

Sanofi Closes Sale of Controlling Stake in Opella to CD&R

Press Release: Annual General Meeting of April 30, 2025
SNY

GlobeNewswire

10 days ago

Press Release: Annual General Meeting of April 30, 2025

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
SNY

GlobeNewswire

10 days ago

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

SNY

GuruFocus.com

10 days ago

Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ...

Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
SNY

Zacks

11 days ago

Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

Regeneron's first-quarter results miss on lower Eylea demand
SNY

Reuters

11 days ago

Regeneron's first-quarter results miss on lower Eylea demand

SNY

Argus Research

11 days ago

Market Digest: SNY, CLS, DPZ, GE, DOC, ROP, SAP, TMO, AGNC

SNY

Argus Research

11 days ago

Analyst Report: Sanofi SA

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
SNY

GlobeNewswire

11 days ago

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

Private Equity Firms Target Defense Assets Once Seen as Toxic
SNY

Bloomberg

12 days ago

Private Equity Firms Target Defense Assets Once Seen as Toxic

Halozyme sues Merck; FDA blames cuts for Vanda delay
SNY

BioPharma Dive

15 days ago

Halozyme sues Merck; FDA blames cuts for Vanda delay

Swiss Agree to Tariff Negotiations With Trump Administration
SNY

Bloomberg

15 days ago

Swiss Agree to Tariff Negotiations With Trump Administration

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
SNY

Investor's Business Daily

15 days ago

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed

Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
SNY

Clinical Trials Arena

16 days ago

Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
SNY

Benzinga

16 days ago

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

SNY

MT Newswires

16 days ago

Sector Update: Health Care Stocks Steady Pre-Bell Thursday

Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
SNY

Zacks

16 days ago

Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth

Sanofi stays on course amid tariff turmoil
SNY

BioPharma Dive

16 days ago

Sanofi stays on course amid tariff turmoil

SNY

MT Newswires

16 days ago

Sanofi's Q1 Earnings, Revenue Rise; 2025 Guidance Confirmed

SNY

MT Newswires

16 days ago

Innate Pharma, Sanofi Finalize Investment

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
SNY

The Wall Street Journal

16 days ago

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug

SNY

GlobeNewswire

16 days ago

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

SNY

MT Newswires

17 days ago

Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement

European pharma companies push for higher drug prices in EU amid U.S. tariff threats
SNY

Reuters

17 days ago

European pharma companies push for higher drug prices in EU amid U.S. tariff threats

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
SNY

Zacks

18 days ago

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
SNY

Zacks

19 days ago

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

SNY

MT Newswires

19 days ago

FDA Approves Dupixent for Chronic Hives in Patients Unresponsive to Antihistamines

Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
SNY

Pharmaceutical Technology

19 days ago

Sanofi and Regeneron’s dupilumab approved by FDA for urticaria

Regeneron, Sanofi announce FDA approval of Dupixent for CSU
SNY

TipRanks

21 days ago

Regeneron, Sanofi announce FDA approval of Dupixent for CSU

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
SNY

GlobeNewswire

22 days ago

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
SNY

GlobeNewswire

22 days ago

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
SNY

BioPharma Dive

22 days ago

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives

SNY

MT Newswires

23 days ago

Sanofi, Earendil Labs Sign Licensing Deal for Autoimmune, Inflammatory Bowel Disease Treatments

Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
SNY

Zacks

23 days ago

Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback

Sanofi licenses immune disease drugs from startup Earendil
SNY

BioPharma Dive

23 days ago

Sanofi licenses immune disease drugs from startup Earendil

Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
SNY

Zacks

24 days ago

Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications

Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement
SNY

PR Newswire

25 days ago

Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement

Tariff wars to hit popular US-made drugs in China, regulator data shows
SNY

Reuters

25 days ago

Tariff wars to hit popular US-made drugs in China, regulator data shows

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
SNY

GlobeNewswire

25 days ago

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Why You Shouldn't Bet Against Sanofi (SNY) Stock
SNY

Zacks

a month ago

Why You Shouldn't Bet Against Sanofi (SNY) Stock

AAN 2025: Sanofi’s tolebrutinib likely to be first BTK inhibitor for the treatment of MS
SNY

Clinical Trials Arena

a month ago

AAN 2025: Sanofi’s tolebrutinib likely to be first BTK inhibitor for the treatment of MS

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’
SNY

Bloomberg

a month ago

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
SNY

GlobeNewswire

a month ago

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Tariffs Stoke Fears That Hung Debt Will Return
SNY

Bloomberg

a month ago

Tariffs Stoke Fears That Hung Debt Will Return

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
SNY

Zacks

a month ago

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions
SNY

Pharmaceutical Technology

a month ago

FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions

Sanofi: Information concerning the total number of voting rights and shares - February 2025
SNY

GlobeNewswire

a month ago

Sanofi: Information concerning the total number of voting rights and shares - February 2025

SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
SNY

Zacks

a month ago

SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
SNY

Zacks

a month ago

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
SNY

GlobeNewswire

a month ago

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Leqembi’s EU review drags on; Sanofi gets a new development head
SNY

BioPharma Dive

a month ago

Leqembi’s EU review drags on; Sanofi gets a new development head

SNY

MT Newswires

a month ago

Nurix Therapeutics Signs Exclusive Licensing Deal With Sanofi for Autoimmune Disease Program

Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?
SNY

Insider Monkey

a month ago

Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?

SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
SNY

Zacks

a month ago

SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients
SNY

Pharmaceutical Technology

a month ago

Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients

FDA Approves Sanofi's Hemophilia Drug
SNY

Benzinga

a month ago

FDA Approves Sanofi's Hemophilia Drug

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
SNY

GlobeNewswire

a month ago

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

SNY

MT Newswires

a month ago

Sanofi Hemophilia Treatment Receives FDA Approval

US FDA approves Sanofi's bleeding disorder therapy
SNY

Reuters

a month ago

US FDA approves Sanofi's bleeding disorder therapy

FDA approves first-of-its-kind RNA drug for hemophilia
SNY

BioPharma Dive

a month ago

FDA approves first-of-its-kind RNA drug for hemophilia

SNY

MT Newswires

a month ago

Regeneron, Sanofi Say Japan Grants Marketing Authorization for Dupixent

Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...
SNY

GuruFocus.com

a month ago

Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
SNY

GlobeNewswire

a month ago

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
SNY

GlobeNewswire

a month ago

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

SNY

Morningstar Research

a month ago

Analyst Report: Sanofi

Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
SNY

Zacks

a month ago

Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive

U.S. to end funding for child vaccines in developing countries, NY Times reports
SNY

TipRanks

a month ago

U.S. to end funding for child vaccines in developing countries, NY Times reports

Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
SNY

Fortune

a month ago

Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate

SNY

Morningstar Research

a month ago

Analyst Report: Sanofi

Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
SNY

Zacks

a month ago

Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag

FDA fast tracks Sanofi’s mRNA vaccine for chlamydia
SNY

Pharmaceutical Technology

a month ago

FDA fast tracks Sanofi’s mRNA vaccine for chlamydia

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
SNY

Zacks

a month ago

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
SNY

GlobeNewswire

a month ago

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
SNY

Zacks

a month ago

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
SNY

GlobeNewswire

a month ago

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

Press Release: Availability of the Q1 2025 Aide mémoire
SNY

GlobeNewswire

2 months ago

Press Release: Availability of the Q1 2025 Aide mémoire

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
SNY

Zacks

2 months ago

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

FedEx downgraded, Adobe upgraded: Wall Street's top analyst calls
SNY

The Fly

2 months ago

FedEx downgraded, Adobe upgraded: Wall Street's top analyst calls

Banks Launch €7.45 Billion Debt Sale for Sanofi Unit Buyout
SNY

Bloomberg

2 months ago

Banks Launch €7.45 Billion Debt Sale for Sanofi Unit Buyout

Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody
SNY

Pharmaceutical Technology

2 months ago

Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody

Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
SNY

Zacks

2 months ago

Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug

Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease
SNY

BioPharma Dive

2 months ago

Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease

SNY

MT Newswires

2 months ago

Sanofi to Acquire Dren Bio's Autoimmune Treatment DR-0201 in $600 Million Deal

Sanofi to acquire Dren Bio's immunology unit
SNY

Reuters

2 months ago

Sanofi to acquire Dren Bio's immunology unit

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
SNY

GlobeNewswire

2 months ago

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Banks Aim to Sell €8.65 Billion Sanofi Buyout Debt Next Week
SNY

Bloomberg

2 months ago

Banks Aim to Sell €8.65 Billion Sanofi Buyout Debt Next Week

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
SNY

PR Newswire

2 months ago

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
SNY

GlobeNewswire

2 months ago

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
SNY

GlobeNewswire

2 months ago

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

CDC plans study into potential vaccines, autism connections, Reuters reports
SNY

TipRanks

2 months ago

CDC plans study into potential vaccines, autism connections, Reuters reports

Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
SNY

Zacks

2 months ago

Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?

SNY

Morningstar Research

2 months ago

Analyst Report: Sanofi

SNY

GlobeNewswire

2 months ago

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Share on Social Networks: